BRIEF-Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint

Reuters12-17 19:45

Dec 17 (Reuters) - PFIZER:

PFIZER: PHASE 3 EV-304 TRIAL SHOWED CLINICALLY MEANINGFUL & STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EVENT-FREE SURVIVAL, & OVERALL SURVIVAL
PFIZER: PATHOLOGIC COMPLETE RESPONSE RATE FOR NEOADJUVANT PADCEV PLUS PEMBROLIZUMAB VERSUS NEOADJUVANT CHEMOTHERAPY WAS MET
PFIZER: PADCEV PLUS KEYTRUDA SIGNIFICANTLY IMPROVES SURVIVAL FOR PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER REGARDLESS OF CISPLATIN ELIGIBILITY
PFIZER: SAFETY PROFILE FOR PADCEV PLUS PEMBROLIZUMAB WAS CONSISTENT WITH KNOWN PROFILE OF TREATMENT REGIMEN

Further company coverage: 4503.T

(((( Reuters.Briefs@thomsonreuters.com ;));))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592944199?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592944199","market":"fut","top_or_hot":-1,"title":"BRIEF-Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint </title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>PFIZER:</p><ul><li><p>PFIZER: PHASE 3 EV-304 TRIAL SHOWED CLINICALLY MEANINGFUL &amp; STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EVENT-FREE SURVIVAL, &amp; OVERALL SURVIVAL</p></li><li><p>PFIZER: PATHOLOGIC COMPLETE RESPONSE RATE FOR NEOADJUVANT PADCEV PLUS PEMBROLIZUMAB VERSUS NEOADJUVANT CHEMOTHERAPY WAS MET</p></li><li><p>PFIZER: PADCEV PLUS KEYTRUDA SIGNIFICANTLY IMPROVES SURVIVAL FOR PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER REGARDLESS OF CISPLATIN ELIGIBILITY</p></li><li><p>PFIZER: SAFETY PROFILE FOR PADCEV PLUS PEMBROLIZUMAB WAS CONSISTENT WITH KNOWN PROFILE OF TREATMENT REGIMEN</p></li></ul><p>Further company coverage: <span>4503.T</span></p><p> (((( Reuters.Briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 19:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint </title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>PFIZER:</p><ul><li><p>PFIZER: PHASE 3 EV-304 TRIAL SHOWED CLINICALLY MEANINGFUL &amp; STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EVENT-FREE SURVIVAL, &amp; OVERALL SURVIVAL</p></li><li><p>PFIZER: PATHOLOGIC COMPLETE RESPONSE RATE FOR NEOADJUVANT PADCEV PLUS PEMBROLIZUMAB VERSUS NEOADJUVANT CHEMOTHERAPY WAS MET</p></li><li><p>PFIZER: PADCEV PLUS KEYTRUDA SIGNIFICANTLY IMPROVES SURVIVAL FOR PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER REGARDLESS OF CISPLATIN ELIGIBILITY</p></li><li><p>PFIZER: SAFETY PROFILE FOR PADCEV PLUS PEMBROLIZUMAB WAS CONSISTENT WITH KNOWN PROFILE OF TREATMENT REGIMEN</p></li></ul><p>Further company coverage: <span>4503.T</span></p><p> (((( Reuters.Briefs@thomsonreuters.com ;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002232.USD","symbol_name":"Allianz Global High Payout USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nP8N3MQ0K0:1","article_id":"2592944199","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592944199","pubTimestamp":1765971902,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint Dec 17  - PFIZER:PFIZER: PHASE 3 EV-304 TRIAL SHOWED CLINICALLY MEANINGFUL & STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EVENT-FREE SURVIVAL, & OVERALL SURVIVALPFIZER: PATHOLOGIC COMPLETE RESPONSE RATE FOR NEOADJUVANT PADCEV PLUS PEMBROLIZUMAB VERSUS NEOADJUVANT CHEMOTHERAPY WAS METPFIZER: PADCEV PLUS KEYTRUDA SIGNIFICANTLY IMPROVES SURVIVAL FOR PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER REGARDLESS OF CISPLATIN ELIGIBILITYPFIZER: SAFETY PROFILE FOR PADCEV PLUS PEMBROLIZUMAB WAS CONSISTENT WITH KNOWN PROFILE OF TREATMENT REGIMENFurther company coverage: 4503.T ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999002232.USD":"Allianz Global High Payout USD","BK4599":"减肥药","BK4581":"高盛持仓","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4592":"伊斯兰概念","LU0058720904.USD":"联博国际健康护理基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","PFE":"辉瑞","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4588":"碎股","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4007":"制药","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus"},"translate_title":"简介-辉瑞表示EV-304 3期临床试验达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1.96},"content_text":"BRIEF-Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint Dec 17 (Reuters) - PFIZER:PFIZER: PHASE 3 EV-304 TRIAL SHOWED CLINICALLY MEANINGFUL & STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EVENT-FREE SURVIVAL, & OVERALL SURVIVALPFIZER: PATHOLOGIC COMPLETE RESPONSE RATE FOR NEOADJUVANT PADCEV PLUS PEMBROLIZUMAB VERSUS NEOADJUVANT CHEMOTHERAPY WAS METPFIZER: PADCEV PLUS KEYTRUDA SIGNIFICANTLY IMPROVES SURVIVAL FOR PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER REGARDLESS OF CISPLATIN ELIGIBILITYPFIZER: SAFETY PROFILE FOR PADCEV PLUS PEMBROLIZUMAB WAS CONSISTENT WITH KNOWN PROFILE OF TREATMENT REGIMENFurther company coverage: 4503.T (((( Reuters.Briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592944199","isCrawlerRequest":true}